British Embassy evaluates prospects for approval of “Sputnik V” in the WHO

The inclusion of the Russian vaccine against COVID Sputnik V in the WHO register of emergency drugs would be a positive step, the British Embassy told RIA Novosti.

British Embassy evaluates prospects for approval of "Sputnik V" in the WHO

“The inclusion of Sputnik V in the WHO Emergency Use Listing (EUL) will be a positive step towards wider acceptance of the vaccine around the world,” the diplomatic mission said.

They said that since November 22, passengers who have completed a full course of vaccination with one of the vaccines in the WHO emergency funds registry are exempt from testing before departure, self-isolation and testing for the eighth day in the UK.

Sputnik V is approved in 70 countries with a total population of 4 billion people, which is more than 50% of the world’s population. Sputnik V ranks second in the world in terms of the number of approvals received by government regulators. The vaccine efficacy was 97.6% based on the analysis of data on 3.8 million vaccinated Russians, which is higher than the data previously published by the medical journal The Lancet (91.6%), the RDIF and the Gamaleya Research Center reported earlier.

In June, the WHO expert group, following the results of inspections carried out in Russia, made a number of comments on the production of the Sputnik V vaccine at the Pharmstandard-UfaVITA enterprise, mainly related to environmental protection and emission monitoring. The experts had no complaints about other enterprises.

In mid-September, the deputy head of the Pan American Health Organization (PAHO), Dr. Jarbas Barbosa, told reporters that the approval of Sputnik V at WHO was suspended until a new inspection of the manufacturer’s plant.

In early October, Russian Health Minister Mikhail Murashko, following a meeting with US representatives in Geneva, said that all barriers to the recognition of the Sputnik V vaccine in WHO had been removed, and some administrative procedures remained.